Inactive Instrument

Press Releases Sigyn Therapeutics, Inc. Other OTC

Equities

SIGY

US82674U1060

Press Releases

Sigyn Therapeutics Reports First Quarter 2024 Financial Results	05-15	AQ
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"	05-07	AQ
Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference	03-05	AQ
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K	02-21	AQ
Sigyn Therapeutics Announces Reverse Stock Split	01-30	AQ
Sigyn Therapeutics Releases Letter to Shareholders	01-04	AQ
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer	12-12	AQ
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results	11-14	AQ
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity	23-10-04	AQ
Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference	23-09-06	AQ
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results	23-08-14	AQ
Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference	23-08-08	AQ
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd	23-07-31	AQ
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application	23-05-17	AQ
Sigyn Therapeutics Reports First Quarter 2023 Financial Results	23-05-16	AQ
SIGYN THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-04-13	AQ
Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer	23-04-11	AQ
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K	23-03-31	AQ
SIGYN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-31	AQ
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results	22-11-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sigyn Therapeutics, Inc. Other OTC

Equities

SIGY

US82674U1060

Press Releases

Filters